ClinicalTrials.gg
RecruitingNCT07732556Updated Jul 29, 2026

Midpoint Transverse Process to Pleura (MTP) Block vs Erector Spinae Plane (ESP) Block for Acute Herpes Zoster (HZ) Pain

An interventional study of Midpoint transverse process to pleura block and Erector spinae plane block in Midpoint Transverse Process to Pleura Block, Erector Spinae Plane Block and Acute Herpes Zoster, sponsored by Tanta University. Recruiting at 1 site in Egypt. Open to participants aged 21 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by Tanta University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
21 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Pain by Tanta University — 10 open to participants now, 10 under way, 1 of them phase 3. Pain · Tanta University.

Planned enrollment
8th of 32
90 · median 70
Started
2026
with 4 others
No phase
30 of 32
9 open now
Registered
28th of 32
by date

Among the 32 studies in Pain by Tanta University, this one is the 8th largest by planned enrollment, is one of 5 that started in 2026, is one of 30 with no phase, and was the 28th registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

10 of the 32 studies in Pain by Tanta University are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 21 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Pain by Tanta University, or all of them as a file.
02

Study summary

The aim of this study is to compare the analgesic efficacy and safety of ultrasound-guided midpoint transverse process block versus ultrasound-guided erector spinae plane block in patients suffering from thoracic herpes zoster pain.

Read the detailed description

Herpes zoster is caused by reactivation of latent varicella-zoster virus in dorsal root or cranial nerve ganglia and commonly presents with unilateral dermatomal rash associated with severe neuropathic pain.

The erector spinae plane block is an ultrasound-guided interfascial plane block in which local anesthetic is deposited deep to the erector spinae muscle adjacent to the transverse process, allowing multidermatomal spread and thoracic analgesia. Recent studies support its efficacy in herpes zoster pain management.

The midpoint transverse process to pleura block is a paravertebral-by-proxy technique where local anesthetic is injected midway between the posterior border of the transverse process and pleura. It may provide thoracic segmental analgesia with lower pleural puncture risk and easier sonoanatomy.

03

Conditions studied

  • Midpoint Transverse Process to Pleura Block
  • Erector Spinae Plane Block
  • Acute Herpes Zoster
  • Pain

Browse trials for

04

Who can participate

Ages eligible
21 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 21-60 years.
  • Both sexes.
  • (ASA) physical status I-II.
  • Acute thoracic herpes zoster within 30 days of rash onset.
  • Moderate to severe pain [numeric rating scale (NRS)≥4].

Exclusion criteria

Exclusion Criteria:

  • Refusal to participate.
  • Coagulopathy or anticoagulant therapy.
  • Infection at puncture site.
  • Allergy to study drugs.
  • Severe psychiatric illness or inability to assess pain.
  • Previous thoracic surgery deformity.
  • Uncontrolled Diabetic patient.
  • Chronic diseases as renal, hepatic, .
  • Patients with chronic disease need analgesia.
  • Patients are coming for more than 3 months (after healing of rash).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Other
    Group MTP

    Patients will receive ultrasound-guided midpoint transverse process to pleura block using 10 mL 0.25% bupivacaine + 40 mg methylprednisolone.

    Other: Midpoint transverse process to pleura block

  • Other
    Group ESP

    Patients will receive ultrasound -guided erector spinae plane block using 10 mL 0.25% bupivacaine + 40 mg methylprednisolone.

    Other: Erector spinae plane block

Interventions

  • OtherMidpoint transverse process to pleura block

    Patients will receive ultrasound-guided midpoint transverse process to pleura block using 10 mL 0.25% bupivacaine + 40 mg methylprednisolone.

  • OtherErector spinae plane block

    Patients will receive ultrasound -guided erector spinae plane block using 10 mL 0.25% bupivacaine + 40 mg methylprednisolone.

06

What researchers measure

Primary outcomes

  1. Incidence of post-herpatic neuralgia

    Incidence of post-herpatic neuralgia will be recorded after 12 weeks of block

    Time frame: After 12 weeks of block

Secondary outcomes

  1. Blood pressure

    Blood pressure will be recoded at time of block and following up at first 24 hours.

    Time frame: 24 hours postoperatively

  2. Heart rate

    Heart rate will be recoded at time of block and following up at first 24 hours.

    Time frame: 24 hours postoperatively

  3. Oxygen saturation

    Oxygen saturation will be recoded at time of block and following up at first 24 hours.

    Time frame: 24 hours postoperatively

  4. Time to first rescue analgesia

    Time to first rescue analgesia will be recorded from the end of surgery till first dose of Acetaminophen administrated.

    Time frame: 24 hours postoperatively

  5. Total rescue analgesics consumption

    Acetaminophen was offered on request as a rescue analgesic at a dosage of 1,000 mg. A maximum daily dosage of 4,000 mg will be permitted for people with Numerical Rating Scale (NRS)≥ 4.

    Time frame: 24 hours postoperatively

  6. Degree of pain

    Pain intensity will be assessed using the Numerical Rating Scale (NRS), where 0 indicates no pain and 10 indicates the worst imaginable pain. NRS will be recorded at 30 minutes, 2 hours, 6 hours, 12 hours, 24 hours, after first 24 hours, 1 week, 2 weeks, 4 weeks, 8 weeks, and 12 weeks postoperatively

    Time frame: 12 weeks postoperatively

  7. Total anti-convulsant drugs

    Total anti-convulsant drugs will be recorded at at 24 hours, 1 week, 2 weeks, 4 weeks, 8 weeks and 12 weeks postoperatively

    Time frame: 12 weeks postoperatively

  8. Assessment of sleep quality

    The Pittsburgh Sleep Quality Index (PSQI) is a 19-item self-report questionnaire will be used to assess the sleep quality. It evaluates seven clinical components: subjective sleep quality, sleep latency, duration, efficiency, disturbances, medication use, and daytime dysfunction. Each of the 7 components is scored on a scale from 0 to 3, where 0 indicates no difficulty and 3 indicates severe difficulty. Subjective Sleep Quality (Self-rated overall quality) Sleep Latency (Time it takes to fall asleep) Sleep Duration (Total hours slept per night) Habitual Sleep Efficiency (Percentage of time in bed spent asleep) Sleep Disturbances (Nighttime awakenings, breathing issues, etc.) Use of Sleeping Medication (Frequency of sleep aids) Daytime Dysfunction (Trouble staying awake or lack of enthusiasm during the day) ≤ 5: Indicates good sleep quality. \> 5: Indicates poor sleep quality.

    Time frame: 12 weeks postoperatively

  9. Incidence of complications

    Incidence of complications such as pneumothorax, local anesthetic systemic toxicity, epidural spread, pleural puncture, and block failure will be recorded.

    Time frame: 24 hours postoperatively

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The data will be available upon a reasonable request from the corresponding author after the end of study for one year.

Supporting information: Study protocol

Time frame: After the end of study for one year.

Access criteria: The data will be available upon a reasonable request from the corresponding author.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jun 2027, 11 months after the start.

Of 3,749 non-industry interventional studies with no phase under Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's planned 11 months is close to that.

Counting every sponsor, half of 3,848 studies reached it within 10 months; a quarter within 4 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2026
First posted
Jul 29, 2026
StartActual
Jul 1, 2026
Primary completionEst.
Jun 1, 2027
CompletionEst.
Jun 1, 2027
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07732556
Lead sponsor
Tanta University
Responsible party
Mohamed Ahmed Kazamel (Resident of Anesthesia, Intensive Care and Pain Management, Tanta University, Egypt., Tanta University) — Principal investigator
First posted
Jul 29, 2026
Start date
Jul 1, 2026
Primary completion
Jun 1, 2027 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Jul 29, 2026

Study contacts

Mohamed A Kazamel, MBBCH
Contact
mohamed198330_pg@med.tanta.edu.eg
00201205997183

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion